Osteoarthritis of the Knee Clinical Trial
Official title:
A Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Three Intra-articular Injections of Ampion™ (4 mL) Administered Two Weeks Apart in Adults With Pain Due to Osteoarthritis of the Knee
NCT number | NCT02242435 |
Other study ID # | AP-008 |
Secondary ID | |
Status | Completed |
Phase | Phase 3 |
First received | |
Last updated | |
Start date | September 2014 |
Est. completion date | May 2015 |
Verified date | August 2022 |
Source | Ampio Pharmaceuticals. Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will evaluate the efficacy of three intra-articular injections, given 2 weeks apart, of Ampion™ in Adults with pain due to osteoarthritis of the knee.
Status | Completed |
Enrollment | 342 |
Est. completion date | May 2015 |
Est. primary completion date | April 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 85 Years |
Eligibility | Inclusion Criteria: 1. Able to provide written informed consent to participate in the study. 2. Willing and able to comply with all study requirements and instructions of the site study staff. 3. Male or female, 40 years to 85 years old (inclusive). 4. Must be ambulatory. 5. Index knee must be symptomatic for greater than 6 months with a clinical diagnosis of OA and supported by radiological evidence (x-ray) acquired at screening and assessed by a central reader. Subjects must have a Kellgren Lawrence Grade of III or IV for inclusion in the study. 6. Moderate to moderately-severe OA pain in the index knee (rating of at least 1.5 on the WOMAC® Index 3.1 5-point Likert Pain Subscale) assessed at screening and confirmed at randomization. 7. Moderate to moderately-severe OA pain in the index knee (even if chronic doses of non-steroidal anti-inflammatory drug [NSAID], which have not changed in the 4 weeks prior to screening, have been/are being used). 8. No analgesia taken 24 hours before efficacy measure. Exclusion Criteria: 1. As a result of medical review and screening investigation, the Principal Investigator considers the subject unfit for the study. 2. Previous Ampion™ injection in the index knee. 3. Known clinically significant liver abnormality (e.g., cirrhosis, transplant, etc). 4. A history of allergic reactions to human albumin (reaction to non-human albumin such as egg albumin is not an exclusion criterion). 5. A history of allergic reactions to excipients in 5% human albumin (N-acetyltryptophan, sodium caprylate). 6. Presence of tense effusions in the index knee. 7. Inflammatory or crystal arthropathies, acute fractures, history of aseptic necrosis or joint replacement in the index knee, as assessed locally by the Principal Investigator. 8. Isolated patella femoral syndrome, also known as chondromalacia, in the index knee. 9. Any other disease or condition interfering with the free use and evaluation of the index knee for the duration of the trial (e.g., cancer, congenital defects, spine OA). 10. Major injury to the index knee within the 12 months prior to screening. 11. Severe hip OA ipsilateral to the index knee. 12. Any pain that could interfere with the assessment of index knee pain (e.g., pain in any other part of the lower extremities, pain radiating to the knee). 13. Any pharmacological or non-pharmacological treatment targeting OA started or changed during the 4 weeks prior to treatment or likely to be changed during the duration of the study. 14. Use of the following medications are exclusionary: 1. IA injected pain medications in the study knee during the study; 2. Analgesics containing opioids. NSAIDs may be continued at levels preceding the study and acetaminophen is available as a rescue medication during the study from the provided supply; 3. Topical treatment on osteoarthritis index knee during the study; 4. Significant anticoagulant therapy (e.g., Heparin or Lovenox) during the study (treatment such as Aspirin and Plavix are allowed); 5. Systemic treatments that may interfere with safety or efficacy assessments during the study; 6. Immunosuppressants; 7. Use of corticosteroids > 10 mg prednisolone equivalent per day (if = 10 mg prednisolone, the dose must be stable). 15. Any human albumin treatment in the 3 months before randomization. |
Country | Name | City | State |
---|---|---|---|
United States | Ampio Pharmaceuticals, Inc. | Englewood | Colorado |
Lead Sponsor | Collaborator |
---|---|
Ampio Pharmaceuticals. Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Knee Pain | Mean Change in WOMAC A Pain (Western Ontario and McMaster Universities Arthritis Index) score from Baseline to 12 weeks. 5-point Likert scale (0=none to 4=extreme). A negative difference constitutes a decrease in pain with a greater negative value indicating a greater reduction in pain. | Scored at Baseline and 20 Weeks | |
Secondary | Change in Knee Function | Mean change in WOMAC C function score (Western Ontario and McMaster Universities Arthritis Index) from Baseline to 12 weeks. 5-point Likert scale indicating limitation of function (0=none to 4=extreme). A greater negative value indicates a improvement in function. | Scored at Baseline and 20 Weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03277066 -
A 4-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Knee Osteoarthritis
|
Phase 2 | |
Recruiting |
NCT03090698 -
Outcomes of Injections in Patients Waiting for Total Knee Replacement
|
Phase 4 | |
Completed |
NCT02556710 -
A Study to Evaluate the Efficacy & Safety of an Intra-Articular Ampion Injection for Pain of Osteoarthritis of the Knee
|
Phase 3 | |
Withdrawn |
NCT02237846 -
Clinical Study of Umbilical Cord Tissue Mesenchymal Stem Cells (UC-MSC) for Treatment of Osteoarthritis
|
Phase 1/Phase 2 | |
Completed |
NCT01849445 -
Targeted Rehabilitation to Improve Outcome After Knee Replacement- A Physiotherapy Study
|
N/A | |
Completed |
NCT02096393 -
Patient Specific Instrumentation in TKR
|
N/A | |
Completed |
NCT01704157 -
A Prospective Study Evaluating the Treatment of Knee Osteoarthritis With the Cryo-Touch III Device
|
N/A | |
Active, not recruiting |
NCT01374230 -
Long-Term Multicenter Evaluation of the E1® Tibial Bearing
|
N/A | |
Completed |
NCT02156440 -
Cross-over Study of the Efficacy and Safety of SierraSil Joint Formula 14 in Osteoarthritis of the Knee
|
Phase 2 | |
Not yet recruiting |
NCT01270412 -
Platelet Rich Plasma (PRP) as a Treatment for Knee Osteoarthritis PRP as a Treatment for Knee Osteoarthritis
|
Phase 2/Phase 3 | |
Completed |
NCT01410409 -
Structured Treatment of Osteoarthritis of the Knee With or Without Total Knee Replacement
|
N/A | |
Completed |
NCT01207115 -
A Study of ABT-652 in Adults With Osteoarthritis Pain of the Knee
|
Phase 2 | |
Completed |
NCT01331278 -
A Comparative Study of Knee Systems
|
Phase 4 | |
Completed |
NCT00970008 -
Exploring Massage Benefits for Arthritis of the Knee
|
Phase 2 | |
Completed |
NCT00988091 -
Investigation of 1.2% Sodium Hyaluronate for Treatment of Painful Chronic Osteoarthritis of the Knee
|
Phase 3 | |
Completed |
NCT00792727 -
HKT-500 in Adult Patients With Osteoarthritis (OA) Knee Pain
|
Phase 3 | |
Completed |
NCT00531427 -
Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee
|
Phase 3 | |
Completed |
NCT00449696 -
Gel-200 Versus Placebo in Osteoarthritis of the Knee
|
Phase 3 | |
Completed |
NCT04145011 -
Coolief Cooled Radiofrequency vs. Conventional Radiofrequency to Manage OA Knee Pain
|
N/A | |
Completed |
NCT01430559 -
Effect Of Meloxicam Versus Placebo In Mainland Chinese Patients With Osteoarthritis Of The Knee
|
N/A |